CORT · Corcept Therapeutics Inc · Financials

$116.52 +4.42 (+3.94%)

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$12.12B

108.10M

Volume · Oct 20 149.35K Avg daily vol (3M) 1.22M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$761.41M +12.8%

FY2025

Net Income

$99.65M -29.4%

FY2025

Gross Margin

98.3% -0.1pp

FY2025

Operating Margin

5.88% -14.4pp

FY2025

Diluted EPS

$0.82 -33.3%

FY2025

Operating Cash Flow

$142M -28.4%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001
Revenue	+23.7%	+16.6%	—	$1.1B – $1.2B	$830.81M	$761.41M^G	$675.04M^G	$482.38M^G	$401.86M^G	$365.98M^G	$353.87M^G	$306.49M	$251.25M	$159.2M	$81.32M	—	—	—	—	—	—	$29K	—	—	—	—	—	—	—	—
Cost of Revenue	+34.1%	+18.4%	+25.3%	—	$14.09M	$12.98M	$10.88M	$6.48M	$5.39M	$5.28M	$5.58M	$5.5M	$5.22M	$3.55M	$2.06M	$1.36M	$882K	$143K	$91K	—	—	—	—	—	—	—	—	—	—	—
Gross Profit	+23.6%	+16.5%	—	—	$816.73M	$748.43M	$664.16M	$475.89M	$396.47M	$360.7M	$348.29M	$300.98M	$246.03M	$155.65M	$79.26M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	98.3%	98.39%	98.66%	98.66%	98.56%	98.42%	98.2%	97.92%	97.77%	97.47%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Research & Development	+24.8%	+17.3%	+32.4%	—	$253.86M	$254.91M	$246.89M	$184.35M	$130.99M	$113.86M	$114.76M	$89.02M	$75.25M	$40.38M	$23.84M	$15.42M	$18.37M	$20.47M	$14.07M	$21M	$18.95M	$14.4M	—	—	—	—	—	—	—	—
General & Administrative	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$11.33M	$8.49M	$5.88M	—	—	—	—	—	—	—	—
Selling, General & Administrative	+43.2%	+33.6%	+28.4%	—	$556.47M	$448.73M	$280.32M	$184.26M	$152.85M	$122.36M	$105.33M	$100.36M	$81.29M	$62.42M	$45.24M	$36.95M	$34.92M	$31.24M	$25.41M	$11.33M	$8.49M	—	—	—	—	—	—	—	—	—
Amortization of Intangibles	—	—	—	—	—	—	—	$465K	$477K	$409K	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Depreciation & Amortization	-3.0%	+17.0%	+22.2%	—	$1.68M	$1.15M	$795K	$1.04M	$1.26M	$1.07M	$525K	$703K	$236K	$106K	$87K	$155K	$141K	$74K	$27K	$3000	$6000	$10K	—	—	—	—	—	—	—	—
Total Operating Expenses	+18.8%	+21.7%	—	—	$52.5M	—	—	—	—	—	—	—	—	—	—	—	$54.17M	$51.85M	$39.58M	$32.33M	$27.44M	$20.28M	—	—	—	—	—	—	—	—
Total Costs & Expenses	+35.3%	+26.0%	+29.6%	—	$824.41M	$716.61M	$538.09M	$375.09M	$289.22M	$241.5M	$225.67M	$194.88M	$161.75M	$106.35M	$71.14M	$53.73M	$54.17M	$51.85M	—	—	—	—	—	—	—	—	—	—	—	—
Operating Income	-26.5%	-19.0%	—	—	$6.41M	$44.8M	$136.95M	$107.28M	$112.63M	$124.48M	$128.2M	$111.61M	$89.5M	$52.86M	$10.18M	-$3.44M	-$27.62M	-$41.5M	-$36.27M	-$32.33M	-$27.44M	-$20.25M	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	5.88%	20.29%	22.24%	28.03%	34.01%	36.23%	36.41%	35.62%	33.2%	12.52%	—	—	—	—	—	—	-69827.59%	—	—	—	—	—	—	—	—
EBITDA	-26.1%	-18.6%	—	—	$8.08M	$45.95M	$137.75M	$108.32M	$113.89M	$125.55M	$128.73M	$112.31M	$89.73M	$52.96M	$10.27M	-$3.29M	-$27.48M	-$41.42M	-$36.25M	-$32.33M	-$27.43M	-$20.24M	—	—	—	—	—	—	—	—
Other Non-Operating Income	+82.6%	—	—	—	$19.96M	$21.67M	$24.54M	$17.28M	$3.56M	$529K	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	-17.0%	-12.8%	—	—	$26.37M	$66.46M	$161.49M	$124.56M	$116.19M	$125.01M	$131.6M	$116.68M	$92.15M	$52.81M	$8.14M	-$6.41M	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Income Tax	—	—	—	—	-$28.81M	-$33.19M	$20.28M	$18.42M	$14.77M	$12.49M	$25.59M	$22.5M	$16.74M	-$76.32M	$0	$0	$0	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income	-0.6%	-1.2%	—	—	$55.18M	$99.65M	$141.21M	$106.14M	$101.42M	$112.51M	$106.01M	$94.18M	$75.41M	$129.12M	$8.14M	-$6.41M	-$31.38M	-$46.01M	-$38.05M	-$32.35M	-$25.97M	-$20.17M	-$20.06M	-$11.57M	-$24.87M	-$20.09M	-$15.54M	-$9.81M	-$18.5M	-$7.45M
Net Margin	—	—	—	—	—	13.09%	20.92%	22%	25.24%	30.74%	29.96%	30.73%	30.01%	81.11%	10.01%	—	—	—	—	—	—	-69537.93%	—	—	—	—	—	—	—	—
Net Income Available to Common Stockholders	-1.0%	-1.5%	—	—	$54.21M	$98.17M	$139.73M	$105.5M	$101.29M	$112.51M	$106.01M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive Income	+0.4%	-0.8%	—	—	$53.33M	$102.13M	$140.38M	$107.62M	$100.78M	$111.87M	$106.17M	$94.51M	$75.42M	$129.05M	$8.14M	-$6.41M	-$31.38M	-$46.01M	-$38.05M	-$32.35M	-$25.97M	-$20.17M	-$20.07M	-$11.57M	-$24.77M	-$20.14M	-$15.6M	-$9.81M	—	—
EPS (Basic) USD/shares	0.0%	+0.6%	—	—	$0.53	$0.95	$1.35	$1.02	$0.95	$0.97	$0.92	$0.82	$0.65	$1.14	$0.07	-$0.06	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS (Diluted) USD/shares	-2.0%	-0.7%	—	—	$0.42	$0.82	$1.23	$0.94	$0.87	$0.89	$0.85	$0.77	$0.60	$1.04	$0.07	-$0.06	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Shares Outstanding (Basic Avg) shares	-0.9%	-2.1%	-0.3%	—	—	103.86M	103.23M	103.56M	106.79M	115.65M	115.41M	114.35M	115.34M	113.53M	110.57M	106.88M	100.98M	99.82M	93.02M	83.31M	68.34M	—	—	—	—	—	—	—	—	—
Shares Outstanding (Diluted Avg) shares	+1.1%	-0.7%	+1.2%	—	—	119.99M	113.48M	111.74M	115.97M	125.96M	124.19M	122.57M	126.69M	124.52M	116.14M	106.88M	100.98M	99.82M	93.02M	83.31M	68.34M	—	—	—	—	—	—	—	—	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $253.16M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Operating lease liabilities	2026-06-30	USD 9,421,000	10-Q filed 2026-07-29
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 1,917,000 Noncurrent operating lease liabilities USD 7,504,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 13.41×

EV/EBIT

—

Peer median 27.84×

P/E (TTM)

266.90×

Peer median 25.23×

Peer medians compare against the 120 similar-size Biotechnology companies (of 559 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1088856 CUSIP 218352102 13F (30d) 49 filings 48 filers Visit website Investor relations